Loading clinical trials...
Loading clinical trials...
A Phase 3, Randomized, Double-blind, Parallel-group, Placebo-controlled, Multicenter Trial to Evaluate the Efficacy and Safety of SEP-363856 in Acutely Psychotic Participants With Schizophrenia
Conditions
Interventions
SEP-363856
Placebo
Locations
73
United States
Pillar Clinical Research LLC - Bentonville Site
Bentonville, Arkansas, United States
Pillar Clinical Research (Little Rock AR) Site
Little Rock, Arkansas, United States
Woodland International Research Group Site
Little Rock, Arkansas, United States
Woodland Research Northwest Site
Rogers, Arkansas, United States
Clinical Innovations, Inc. dba CITrials (Bellflower)
Bellflower, California, United States
ProScience Research Group Site
Culver City, California, United States
Start Date
February 28, 2025
Primary Completion Date
October 20, 2026
Completion Date
October 29, 2026
Last Updated
April 23, 2026
NCT04226898
NCT05240976
NCT07455929
NCT05304767
NCT06745479
NCT06740383
Lead Sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions